RYRongcun Yang

Rongcun Yang

*This is an algorithmically generated author record based on publicly available information.

Rongcun Yang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Anju Zhang

    Department of Molecular Pathology, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden

    1 shared publication
  • Astrid Gruber

    Department of Medicine, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden

    1 shared publication
  • Dawei Xu

    Department of Medicine, Division of Hematology, Bioclinicum and Center for Molecular Medicine, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden

    1 shared publication
  • F. Chen

    Microbiology and Tumor Biology Center (MTC), Karolinska Institute, S‐171, 76 Stockholm, Sweden

    1 shared publication
  • G. K. Hansson

    Division of Hematology and Infectious Disease, Department of Medicine, Karolinska Hospital, S‐171 77 Stockholm

    1 shared publication
  • R. Kiessling

    Immuno‐ and Gene‐therapy Laboratory, Cancer Center of Karolinska (CCK)

    1 shared publication

Latest Publications

  • Hyaluronic Acid and Chondroitin Sulphate A Rapidly Promote Differentiation of Immature DC with Upregulation of Costimulatory and Antigen‐Presenting Molecules, and Enhancement of NF‐κB and Protein Kinase Activity

    by R. Yang, Z. Yan, F. Chen, G. K. Hansson, R. Kiessling

    Dendritic cells (DCs) have been identified as effective antigen‐presenting cells (APCs). We demonstrate that extracellular matrix (ECM), hyaluronic acid (HA) and chondroitin sulphate A (CSA), in the presence of granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), can rapidly promote the differentiation of monocyte‐derived immature DCs, as characterized by the remarkable upregulation of human leucocyte antigen (HLA‐DR), CD40, CD54, CD80 and CD86 expression to levels higher than those in the DCs generated by culturing with GM‐CSF and interleukin (IL)‐4 for 7 days and aggregation of the cells within 48 h. The upregulation of expression of HLA‐DR, CD40, CD54, CD80 and CD86 was dose‐dependent. Further studies showed that HA and CSA were able to augment nuclear factor (NF)‐κB activity, as determined by gel mobility shift assay and promote protein phosphorylation. Inhibition of NF‐κB by pyrolidine dithiocarbamate and sodium salicylate, and serine‐threonine and tyrosine kinase by starosporine as well as phosphatidylinositide‐3‐kinase (PI‐3‐K) by wortmannin could prevent the effects of HA and CSA on the expression of HLA‐DR, CD40, CD80 and CD86 in various degrees. Thus, our data demonstrate that HA or CSA can effectively and rapidly promote the differentiation of immature DC, suggesting that HA and CSA may possess a potential capacity in regulating immune responses.


  • Immature dendritic cells kill ovarian carcinoma cells by a FAS/FASL pathway, enabling them to sensitize tumor-specific CTLs

    by Rongcun Yang, Dawei Xu, Anju Zhang, Astrid Gruber

    Dendritic cells (DCs) can acquire antigen(s) from apoptotic tumor cells, resulting in an immunogen that can induce class I‐restricted cytotoxic T lymphocytes (CTLs) and protective tumor rejection. Here, we investigated whether DCs derived from ascitic monocytes of patients with ovarian carcinoma could kill autologous ovarian tumor cells and if as a result they would acquire antigen(s) enabling them to induce a tumor‐specific immunity. We found that the immature DCs could exert a significant cytotoxicity towards autologous and allogeneic ovarian tumor cells. This cytotoxicity was independent of Ca2+ and could be inhibited by anti‐Fas IgG1 monoclonal antibody, indicating the involvement of the Fas/Fas ligand (FasL) pathway in the cytotoxic mechanism. Further supporting this conclusion, the ascitic monocyte‐derived DCs expressed high levels of FasL mRNA and intracellular FasL and significant levels of Fas were also revealed on the surface of ovarian tumor cells. Coculture of DCs induced apoptosis in ovarian carcinoma cells, as well as uptake of apoptotic tumor cells into the cytoplasma of the DCs, as visualized by immunofluoresence. Autologous DCs cocultured with apoptotic ovarian tumor cells were able to specifically stimulate tumor‐specific CTLs, whereas DCs cocultured with necrotic ovarian cells were unable to do so. Collectively, these results demonstrate that immature DCs can kill autologous ovarian carcinoma cells via the Ca2+‐independent Fas/FasL pathway and that this may have important consequences for their ability to stimulate tumor‐specific CTLs.